30-minute cancer test being developed for doctors' offices
February 13, 2014 - CBC News - The Atlantic Cancer Research Institute has developed a cancer-detecting test that could be done in a doctor's office using a small sample of bodily fluid, such as saliva or urine, instead of a biopsy.
* Article published by CBC News on Feb 13, 2014
New England Peptide, Inc. and ACRI Launch New Biotech Company, Excipio Technologies, inc. to Study Exosome Isolation
December 3, 2013 - New England Peptide (NEP), a Massachusetts based biotech manufacturer, and The Atlantic Cancer Research Institute (ACRI), a leading cancer research center in Atlantic Canada, have launched a new biotech company. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both NEP and ACRI for the isolation of exosomes and extracellular microvesicles.
A new biosciences company in New Brunswick
John Betts, MLA Moncton-Cresent
Honourable Marie-Claude Blais, Minister of Education and Early Childhood Development and Minister responsible of Women's equality
Rodney Ouellette, M.D., Ph.D, President and Scientific Director, ACRI
Sam Massoni, President, New England Peptide
NB Premier, Honourable David Alward
Doug Robertson, President and Chief Executive Officer, Venn
November 8, 2013 – The Atlantic Cancer Research Institute (ACRI), a leading cancer research centre in Atlantic Canada, and New England Peptide (NEP), a Boston based biotech manufacturer, have launched a new company to be based in Moncton, NB. Excipio Technologies Inc. has a mandate to commercialize the Vn96 peptide developed by both ACRI and NEP.
New England Peptide, Atlantic Cancer Research Institute Mark Next Step in Cancer Fight
July 25, 2011 - New England Peptide (NEP) and the Atlantic Cancer Research Institute (ACRI) announced today that they have jointly submitted a patent application for cancer-related peptide reagents which have the potential to deliver breakthroughs in cancer diagnostics and more individualized therapies for cancer patients.